Time‐dependent effects of hormone‐deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging
Open Access
- 2 July 2001
- journal article
- research article
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 46 (1) , 49-57
Abstract
Combined MRI and 3D spectroscopic imaging (MRI/3D‐MRSI) was used to study the metabolic effects of hormone‐deprivation therapy in 65 prostate cancer patients, who underwent either short, intermediate, or long‐term therapy, compared to 30 untreated control patients. There was a significant time‐dependent loss of the prostatic metabolites choline, creatine, citrate, and polyamines during hormone‐deprivation therapy, resulting in the complete loss of all observable metabolites (total metabolic atrophy) in 25% of patients on long‐term therapy. The amount and time‐course of metabolite loss during therapy significantly differed for healthy and malignant tissues. Citrate levels decreased faster than choline and creatine levels during therapy, resulting in an increase in the mean (choline + creatine)/citrate ratio with duration of therapy. Due to a loss of all MRSI detectable citrate, this ratio could not be used to identify cancer in 69% of patients on long‐term therapy. In the absence of citrate, however, residual prostate cancer could still be detected by elevated choline levels (choline/creatine ratio ≥1.5), or the presence of only choline in the proton spectrum. The loss of citrate and the presence of total metabolic atrophy correlated roughly with decreasing serum prostatic specific antigen levels with increasing therapy. In summary, MRI/3D‐MRSI provided both a measure of residual cancer and a time‐course of metabolic response following hormone‐deprivation therapy. Magn Reson Med 46:49–57, 2001.Keywords
This publication has 36 references indexed in Scilit:
- Three-Dimensional Magnetic Resonance Spectroscopic Imaging of Brain and Prostate CancerNeoplasia, 2000
- THE PROSTATE: MR IMAGING AND SPECTROSCOPYRadiologic Clinics of North America, 2000
- THE BIOLOGY OF HORMONE REFRACTORY PROSTATE CANCERUrologic Clinics of North America, 1999
- Mechanistic Concepts in Androgen-dependence of Prostate CancerCancer and Metastasis Reviews, 1998
- Pathological changes in prostate lesions after androgen manipulation.Journal of Clinical Pathology, 1998
- Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2–3 N0 M0 prostatic carcinomaUrology, 1997
- Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II studyBritish Journal of Urology, 1997
- WHY NEOADJUVANT ANDROGEN DEPRIVATION PRIOR TO RADICAL PROSTATECTOMY IS UNNECESSARYUrologic Clinics of North America, 1996
- Biochemical and Pathological Effects of 8 Months of Neoadjuvant Androgen Withdrawal Therapy Before Radical Prostatectomy in Patients with Clinically Confined Prostate CancerJournal of Urology, 1996
- Neoadjuvant Hormonal Therapy Before Radical Prostatectomy Decreases the Number of Positive Surgical Margins in Stage T2 Prostate Cancer: Interim Results of a Prospective Randomized TrialJournal of Urology, 1995